Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Ranked against 24 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TBPH | $884M | 8.3× | — | 8.2× | 66.9% | — | 98.5% | 35.7% | 35.7% | — | 1 |
| CYRX | $876M | 12.3× | — | 5.0× | 12.4% | 47.1% | 44.4% | 15.6% | 15.6% | — | 26 |
| ARDX | $782M | — | — | 1.9× | 22.1% | 90.3% | -15.1% | -36.9% | -16.7% | — | 30 |
| COLL | $775M | 13.8× | 3.0× | 1.0× | 23.6% | 59.3% | 8.1% | 20.8% | 20.8% | -1.3× | 40 |
| LXRX | $632M | — | — | 12.7× | 60.2% | 99.4% | -101% | -46.8% | -31.2% | — | 18 |
| ACRS | $615M | — | — | 78.6× | -58.2% | 73.3% | -830% | -63.0% | -63.0% | — | 20 |
| ZVRA | $610M | 7.6× | — | 5.7× | 351% | — | 78.2% | 53.8% | 38.4% | — | 27 |
| IRWD | $578M | 23.3× | 3.6× | 1.9× | -15.7% | — | 8.1% | -9.2% | -9.2% | -2.2× | 36 |
| PBYI | $539M | 17.1× | 14.7× | 2.4× | -0.9% | 74.5% | 13.6% | 23.9% | 17.7% | 0.4× | 31 |
| AMRN | $509M | — | — | 2.4× | -6.5% | 56.6% | -18.2% | -8.4% | -8.4% | — | 9 |
| GYRE | $484M | 228.0× | 31.1× | 4.2× | 10.2% | 95.4% | 8.5% | 15.8% | 15.8% | -3.5× | 7 |
| SVA | $465M | — | — | 1.2× | 6.8% | 67.9% | -51.5% | -4.5% | -4.0% | — | 2 |
| CRMD | $447M | 2.8× | 2.0× | 1.4× | 617% | 88.5% | 52.3% | 40.2% | 40.2% | -1.0× | 24 |
| VREOF | $385M | — | 18.8× | 1.4× | 170% | 47.3% | -25.3% | -22.2% | -22.2% | -6.8× | — |
| EBS | $349M | 7.3× | 3.6× | 0.5× | -28.8% | 56.1% | 7.1% | 10.1% | 4.8% | 1.9× | 29 |
| QTTB | $265M | 3.7× | 12.6× | 4.9× | — | — | 55.5% | 71.0% | 71.0% | -2.8× | 3 |
| ELTP | $248M | 7.7× | 4.3× | 1.7× | 77.1% | 50.4% | 30.1% | 45.4% | 45.4% | -0.6× | — |
| SIGA | $218M | 9.5× | 2.6× | 2.3× | -31.8% | 68.6% | 24.6% | 11.7% | 11.7% | -6.4× | 25 |
| PYXS | $216M | — | — | 15.6× | -14.2% | 82.8% | -575% | -149% | -149% | — | 10 |
| NATR | $216M | 11.6× | 3.1× | 0.5× | 5.7% | 72.4% | 4.1% | 12.1% | 12.1% | -2.4× | 19 |
| AKBA | $196M | — | 2.4× | 0.8× | 47.5% | 83.3% | -2.3% | -16.4% | -6.6% | -5.5× | 27 |
| WHWK | $185M | — | — | 25.9× | -72.5% | 89.4% | -288% | -15.1% | -15.1% | — | 10 |
| MGNX | $153M | — | — | 1.0× | -0.3% | 100% | -49.9% | -134% | -134% | — | 18 |
| DERM | $146M | — | — | 2.4× | 10.2% | 66.2% | -18.5% | -35.9% | -20.0% | — | 4 |
| BGM | $127M | — | — | 3.4× | 51.1% | 16.6% | -52.6% | -5.1% | -5.1% | — | — |
Peers = companies sharing SVA's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -4%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $488.2M covers the $229.4M due within a year 2.1× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (20-F).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~2.0% on $494.9M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
What the company returns to shareholders — and whether it's covered by cash.
Free-cash-flow coverage unavailable. Last year: $3.53B dividends + $0 buybacks = $3.53B returned on -$561.1M FCF.
3 consecutive years of dividend increases · 27%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-10-28
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $386.0M 100.0% | $361.4M 100.0% | $470.2M 100.0% | $1.47B 100.0% | $19.37B 100.0% | $510.6M 100.0% | $246.1M 100.0% | — | $229.7M 100.0% | $174.3M 100.0% |
| Cost of Revenue | $124.0M 32.1% | $140.7M 38.9% | $146.9M 31.2% | $658.2M 44.7% | $988.9M 5.1% | $67.2M 13.2% | $32.5M 13.2% | — | $24.7M 10.8% | $20.2M 11.6% |
| Gross Profit | $262.0M 67.9% | $220.7M 61.1% | $323.3M 68.8% | $815.2M 55.3% | $18.38B 94.9% | $443.4M 86.8% | $213.6M 86.8% | — | $204.9M 89.2% | $154.1M 88.4% |
| Research & Development | $216.2M 56.0% | $270.7M 74.9% | $350.2M 74.5% | $478.7M 32.5% | $152.7M 0.8% | $48.8M 9.5% | $24.3M 9.9% | — | $21.9M 9.5% | $20.5M 11.8% |
| Selling, General & Admin | $333.0M 86.3% | $420.9M 116.5% | $598.3M 127.2% | $836.1M 56.7% | $602.1M 3.1% | $176.5M 34.6% | $121.5M 49.4% | — | $137.0M 59.7% | $87.4M 50.1% |
| Total Operating Expenses | $752.1M 194.8% | $726.2M 201.0% | $1.04B 220.6% | $1.32B 89.9% | $758.1M 3.9% | $227.8M 44.6% | $145.0M 58.9% | — | $159.6M 69.5% | $108.7M 62.3% |
| Operating Income | -$490.1M -127.0% | -$505.5M -139.9% | -$714.0M -151.9% | -$509.0M -34.5% | $17.62B 91.0% | $215.6M 42.2% | $68.6M 27.9% | — | $45.3M 19.7% | $45.4M 26.0% |
| Interest Expense | $9.8M 2.5% | $5.6M 1.6% | $4.9M 1.1% | $1.3M 0.1% | $2.8M 0.0% | $1.5M 0.3% | $650K 0.3% | — | $1.1M 0.5% | $1.6M 0.9% |
| Interest & Investment Income | $33.3M 8.6% | $29.1M 8.0% | $87.1M 18.5% | $157.4M 10.7% | $102.6M 0.5% | $1.9M 0.4% | $2.0M 0.8% | — | $2.0M 0.9% | $1.2M 0.7% |
| Other Income (Expense), net | $208.6M 54.0% | $527.6M 146.0% | $558.8M 118.8% | $296.6M 20.1% | -$153.0M -0.8% | $496K 0.1% | $912K 0.4% | — | $321K 0.1% | $13K 0.0% |
| Pretax Income | -$262.1M -67.9% | $42.8M 11.9% | -$84.5M -18.0% | -$48.5M -3.3% | $17.57B 90.7% | $216.6M 42.4% | $70.8M 28.8% | — | $46.6M 20.3% | $45.0M 25.8% |
| Income Tax Expense | -$63.3M -16.4% | $2.2M 0.6% | $36.4M 7.7% | $11.5M 0.8% | $3.45B 17.8% | $31.4M 6.2% | $5.6M 2.3% | — | $10.5M 4.6% | $8.3M 4.8% |
| Net Income | -$198.8M -51.5% | $40.7M 11.3% | -$13.5M -2.9% | $14.5M 1.0% | $8.12B 41.9% | $110.4M 21.6% | $44.9M 18.3% | — | $21.8M 9.5% | $25.8M 14.8% |
| Per Share | ||||||||||
| EPS (Basic) | -$0.83 | $1.27 | -$0.19 | $0.20 | $113.54 | $1.06 | $0.42 | $0.63 | $0.34 | $0.45 |
| EPS (Diluted) | -$0.83 | $1.27 | -$0.19 | $0.20 | $113.44 | $0.97 | $0.41 | $0.63 | $0.34 | $0.45 |
| Weighted Avg Shares (Basic) | 71.9M | 71.9M | 71.8M | 71.7M | 71.5M | 98.9M | 94.9M | 71.1M | 64.7M | 57.0M |
| Weighted Avg Shares (Diluted) | 71.9M | 71.9M | 71.9M | 71.8M | 71.6M | 113.7M | 109.7M | 71.3M | 65.0M | 57.1M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
A reverse discounted cash flow is not shown for a company with no positive EBITDA.
No positive EBITDA in the recent record, so there is no return on capital to compare against its cost.
Classified from the filings: EBITDA negative in each of the last 2 years.
Top 3 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-10-28
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -4% against ROIC -4% — -0% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -3.1% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | 13.2 | 13.2 | 5.1 | 44.7 | 31.2 | 38.9 | 32.1 |
| Gross Profit | — | 86.8 | 86.8 | 94.9 | 55.3 | 68.8 | 61.1 | 67.9 |
| R&D | — | 9.9 | 9.5 | 0.8 | 32.5 | 74.5 | 74.9 | 56.0 |
| SG&A | — | 49.4 | 34.6 | 3.1 | 56.7 | 127.2 | 116.5 | 86.3 |
| Operating Income | — | 27.9 | 42.2 | 91.0 | -34.5 | -151.9 | -139.9 | -127.0 |
| Income Tax | — | 2.3 | 6.2 | 17.8 | 0.8 | 7.7 | 0.6 | -16.4 |
| Net Income | — | 18.3 | 21.6 | 41.9 | 1.0 | -2.9 | 11.3 | -51.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SVA: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2017 | 88.4% | 26.0% | 14.8% |
| FY2018 | 89.2% | 19.7% | 9.5% |
| FY2019 | 86.8% | 27.9% | 18.3% |
| FY2020 | 86.8% | 42.2% | 21.6% |
| FY2021 | 94.9% | 91.0% | 41.9% |
| FY2022 | 55.3% | -34.5% | 1.0% |
| FY2023 | 68.8% | -151.9% | -2.9% |
| FY2024 | 61.1% | -139.9% | 11.3% |
| FY2025 | 67.9% | -127.0% | -51.5% |
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: positive EBIT.
Accruals are positive and DSO is up +150 days over 3 years — profit is being recognised ahead of collection.
Reported free cash flow is -$561M; after share-based compensation it is -$561M. The difference is a real cost that the cash flow statement adds back.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
Ladder as of 2025-12-31 (20-F); cash from the 2025-12-31 balance sheet; FCF from FY2025. Free cash flow is negative, so projected resources fall rather than accumulate.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: ebitda.
No positive free cash flow to discount, so the price cannot be expressed as a growth requirement.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: free_cash_flow.
| Step | Amount | Running total |
|---|---|---|
| Net income | −$199M | −$199M |
| Share-based comp | $0 | −$199M |
| Other non-cash & working capital | −$313M | −$512M |
| Operating cash flow | −$512M | −$512M |
| Capex | −$49M | −$561M |
| Free cash flow | −$561M | −$561M |
| FCF after SBC | −$561M | −$561M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | 107.5% | 122.9% | 15.3 points |
| FY2021 | 3692.5% | 271.9% | -3420.6 points |
| FY2022 | -92.4% | -48.4% | 44.0 points |
| FY2023 | -68.1% | -12.7% | 55.4 points |
| FY2024 | -23.1% | -29.2% | -6.1 points |
| FY2025 | 6.8% | -4.8% | -11.7 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 168.7 days | 313 days | 65 days | 416.7 days |
| FY2020 | 181.2 days | 574.9 days | 165.9 days | 590.1 days |
| FY2021 | 17.8 days | 144.3 days | 21.6 days | 140.5 days |
| FY2022 | 120.5 days | 97.2 days | 11 days | 206.7 days |
| FY2023 | 329.9 days | 337.1 days | 32.2 days | 634.8 days |
| FY2024 | 303.9 days | 251.4 days | 31.8 days | 523.6 days |
| FY2025 | 270.8 days | 277.5 days | 47.8 days | 500.5 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | 1.3 percent |
| FY2020 | -19.4 percent |
| FY2021 | -43.0 percent |
| FY2022 | 5.8 percent |
| FY2023 | -1.1 percent |
| FY2024 | 0.8 percent |
| FY2025 | 3.7 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Below the line for 3 consecutive years to the latest.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.